The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,007
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors
Agarwal, S., Hynes, P. G., Sheppard, H., Lake, R. G., Abou-Kheir, W. G., Fang, L., Casey, O. M., Ameri, A. H., Martin, P. L., Yin, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.077 · Cited by 61
Self-citationCopy number variations in urine cell free DNA as biomarkers in advanced prostate cancer
Xia, Y. F., Huang, C., Dittmar, R. L., Du, M., Wang, Y., Liu, H., Shenoy, N. K., Wang, L., & Kohli, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9027 · Cited by 59
The Genomics of Prostate Cancer: emerging understanding with technologic advances
Rubin, M. A., & Demichelis, F. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.166 · Cited by 59
Self-citationNPRL2 enhances autophagy and the resistance to Everolimus in castration‐resistant prostate cancer
Chen, Z., Jiang, Q., Zhu, P., Chen, Y., Xie, X., Du, Z., Li, J., & Tang, W. (2018) · The Prostate · doi:10.1002/pros.23709 · Cited by 61
Self-citationGenetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate
Elfandy, H., Armenia, J., Pederzoli, F., Pullman, E., Pértega‐Gomes, N., Schultz, N. D., Viswanathan, K., Vosoughi, A., Blattner, M., Stopsack, K. H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0440 · Cited by 60
Self-citationHomologous Recombination and Replication Fork Protection: BRCA2 and More!Preprint
Feng, W., & Jasin, M. (2017) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2017.82.035006 · Cited by 66
van der Doelen, M. J., Velho, P. I., Slootbeek, P. H. J., Naga, S. P., Bormann, M., van Helvert, S., Kroeze, L. I., van Oort, I. M., Gerritsen, W. R., Antonarakis, E. S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.001 · Cited by 59
Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma
Jiang, T., Fang, Z., Tang, S., Cheng, R., Li, Y., Ren, S., Su, C., Min, W., Guo, X., Zhu, W., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.128 · Cited by 60
Palmbos, P. L., Daignault‐Newton, S., Tomlins, S. A., Agarwal, N., Twardowski, P. W., Morgans, A. K., Kelly, W. K., Arora, V. K., Antonarakis, E. S., Siddiqui, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0024 · Cited by 58
Self-citationCYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Alex, A. B., Pal, S. K., & Agarwal, N. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016642370 · Cited by 64
Emerging data on androgen receptor splice variants in prostate cancer
Cao, S., Zhan, Y., & Dong, Y. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0298 · Cited by 62
Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer
Labidi‐Galy, S. I., Olivier, T., Rodrigues, M. J., Ferraioli, D., Derbel, O., Bodmer, A., Petignat, P., Rak, B., Chopin, N., Trédan, O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2136 · Cited by 59
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Mohamed, A. A. M., Xavier, C. P., Sukumar, G., Tan, S., Ravindranath, L., Seraj, N., Kumar, V., Sreenath, T., McLeod, D. G., Petrovics, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2949 · Cited by 58
Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?
Rao, A., Vapiwala, N., Schaeffer, E. M., & Ryan, C. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239041 · Cited by 58
Mutation of the PTCH1 gene predicts recurrence of breast cancer
Wang, C., Chang, Y.-C., Kuo, Y., Lee, K., Chen, P., Cheung, C. H. A., Chang, C., Phan, N. N., Shen, M., & Hsu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-52617-4 · Cited by 58
Ma, J., Bai, J., Zhang, H., Jia, J., Shi, Q., Yang, C., Wang, X., He, D., & Guo, P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2671-1 · Cited by 61
Discovery of Novel Androgen Receptor Ligands by Structure-Based Virtual Screening and Bioassays
Zhou, W., Duan, M., Fu, W., Pang, J., Tang, Q., Sun, H., Xu, L., Chang, S., Li, D., & Hou, T. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.03.007 · Cited by 57
Molecular Trajectory of BRCA1 and BRCA2 Mutations
Hatano, Y., Tamada, M., Matsuo, M., & Hara, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00361 · Cited by 58
Agarwal, N., Azad, A., Shore, N. D., Carles, J., Fay, A. P., Dunshee, C. J., Karsh, L. I., Paccagnella, M. L., Santo, N. D., Elmeliegy, M. A., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-0811 · Cited by 57
Li, X., Wang, Y., Deng, S., Zhu, G., Wang, C., Johnson, N. A., Zhang, Z., Tirado, C. R., Xu, Y., Metang, L. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.010 · Cited by 61
The Molecular Evolution of Castration-resistant Prostate Cancer
Ceder, Y., Bjartell, A. S., Čulig, Z., Rubin, M. A., Tomlins, S. A., & Visakorpi, T. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.11.012 · Cited by 57
Self-citationAndrogen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
Norris, J. D., Miner, S. J., Baker, J. G., Stagg, D. B., Wardell, S. E., Park, S. H., Alley, H. M., Baldi, R. M., Yllanes, A. P., Andreano, K. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87328 · Cited by 57
Samaranayake, G. J., Troccoli, C. I., Huynh, M. Q., Lyles, R. D. Z., Kage, K., Win, A., Lakshmanan, V., Kwon, D., Ban, Y. J., Chen, S. X., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01269-x · Cited by 56
CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools
Chmielewski, J. P., Bowlby, S. C., Wheeler, F. B., Shi, L., Sui, G., Davis, A. L., Howard, T. D., D'Agostino, R. B., Miller, L. D., Sirintrapun, S. J., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0526 · Cited by 60
Ikeda, S., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1523849 · Cited by 59
Shan, J., Al-Muftah, M., Alkowari, M. K., Abuaqel, S. W. J., Al‐Rumaihi, K., Al‐Bozom, I., Li, P., & Chouchane, L. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0218-y · Cited by 57
Cytoreductive treatment strategies for de novo metastatic prostate cancer
Connor, M. J., Shah, T. T., Horan, G., Bevan, C. L., Winkler, M. H., & Ahmed, H. U. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0284-3 · Cited by 56
The landscape of RNA polymerase II–associated chromatin interactions in prostate cancer
Ramanand, S. G., Chen, Y., Yuan, J., Daescu, K., Lambros, M. B. K., Houlahan, K. E., Carreira, S., Yuan, W., Baek, G., Sharp, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134260 · Cited by 54
Self-citationDNA Damage Response in Prostate CancerPreprint
Schiewer, M. J., & Knudsen, K. E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030486 · Cited by 58
Leibold, J., Ruscetti, M. A., Cao, Z., Ho, Y.-J., Baslan, T., Zou, M., Abida, W. M., Feucht, J., Han, T., Barriga, F. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1242 · Cited by 56
Self-citationGenome-wide crosstalk between steroid receptors in breast and prostate cancers
Paakinaho, V., & Palvimo, J. (2021) · Endocrine-Related Cancer · doi:10.1530/erc-21-0038 · Cited by 35
Wu, C., Peng, S., Pilie, P. G., Geng, C., Park, S., Manyam, G. C., Lu, Y., Yang, G., Tang, Z., Kondraganti, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0848 · Cited by 55
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer
Aggarwal, R. R., Rydzewski, N. R., Zhang, L., Foye, A., Kim, W. K., Helzer, K. T., Bakhtiar, H., Chang, S. L., Perry, M. D., Gleave, M. E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3987 · Cited by 55
Self-citationSridaran, D., Chouhan, S., Mahajan, K. N., Renganathan, A., Weimholt, C., Bhagwat, S., Reimers, M. A., Kim, E. H., Thakur, M. K., Saeed, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34724-5 · Cited by 59
Self-citationTargeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
Nambiar, D. K., Mishra, D., & Singh, R. P. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028310 · Cited by 58
Martin, P. L., Yin, J.-J., Seng, V., Casey, O. M., Corey, E., Morrissey, C. M., Simpson, R. M., & Kelly, K. (2016) · Oncogene · doi:10.1038/onc.2016.223 · Cited by 56
Wei, X. X., Hsieh, A. C., Kim, W. K., Friedlander, T. W., Lin, A., Louttit, M., & Ryan, C. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0432 · Cited by 56
Cabel, L., Loir, E., Gravis, G., Lavaud, P., Massard, C., Albiges, L. K., Baciarello, G., Loriot, Y., & Fizazi, K. S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0232-7 · Cited by 57
Chen, M., Wan, L., Zhang, J., Zhang, J., Mendez, L., Clohessy, J. G., Berry, K., Victor, J., Yin, Q., Zhu, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02272-y · Cited by 61
Millis, S. Z., Jardim, D. L. F., Albacker, L. A., Ross, J. S., Miller, V. A., Ali, S. M., & Kurzrock, R. (2018) · Cancer · doi:10.1002/cncr.31921 · Cited by 56
Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer
Sonpavde, G., Agarwal, N., Pond, G. R., Nagy, R. J., Nussenzveig, R. H., Hahn, A. W., Sartor, O. A., Gourdin, T. S., Nandagopal, L., Ledet, E. M., et al. (2019) · Cancer · doi:10.1002/cncr.31959 · Cited by 54
Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis
Sun, J. M., Li, S., Wang, F., Fan, C., & Wang, J. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0923-7 · Cited by 57
Dessai, A. S., Domínguez, M. P., Chen, U.-I., Hasper, J., Prechtl, C., Yu, C. R., Katsuta, E., Dai, T., Zhu, B., Jung, S. Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1708 · Cited by 59
Immunotherapy for Prostate CancerPreprint
Venturini, N. J., & Drake, C. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030627 · Cited by 59
Ending Mozambique's War: The Role of Mediation and Good Offices
Hume, C. R. (1994) · Virtual Defense Library (Ministerio de Defensa) · Cited by 122
Deng, G., Wang, R., Sun, Y., Huang, C., Yeh, S., You, B., Feng, C., Li, G., Ma, S., & Chang, C. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00743-w · Cited by 55
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
Rebuzzi, S. E., Rescigno, P., Catalano, F., Mollica, V., Vogl, U. M., Marandino, L., Massari, F., Mestre, R. P., Zanardi, E., Signori, A., et al. (2022) · Cancers · doi:10.3390/cancers14051245 · Cited by 56
Zhang, J., Wei, J., Sun, R., Sheng, H., Yin, K., Pan, Y., Jiménez, R. E., Chen, S., Cui, X., Zou, Z., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.024 · Cited by 58
Advances in Prostate Cancer Biomarkers and Probes
Li, K., Wang, Q., Tang, X., Akakuru, O. U., Li, R., Wang, Y., Zhang, R., Jiang, Z., & Yang, Z. (2024) · Cyborg and Bionic Systems · doi:10.34133/cbsystems.0129 · Cited by 57
“Robinson et al. [112] conducted prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from 150 patients with metastatic castration resistant prostate cancer (mCRPC).”
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis
Faltermeier, C. M., Drake, J. M., Clark, P. M., Smith, B. A., Zong, Y., Volpe, C., Mathis, C., Morrissey, C. M., Castor, B., Huang, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521674112 · Cited by 55
Driehuis, E., & Clevers, H. C. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13758 · Cited by 55
Hotte, S. J., Chi, K. N., Joshua, A. M., Tu, D., Macfarlane, R. J., Gregg, R. W., Ruether, J. D., Basappa, N. S., Finch, D. L., Salim, M., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.005 · Cited by 55
He, L., Fang, H., Chen, C., Wu, Y., Wang, Y., Ge, H., Wang, L., Wan, Y., & He, H. (2020) · Medicine · doi:10.1097/md.0000000000019760 · Cited by 55
Self-citationWen, S., He, Y., Wang, L., Zhang, J., Quan, C., Niu, Y., & Huang, H. (2020) · Oncogene · doi:10.1038/s41388-020-01456-z · Cited by 55
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, J. M., Helzer, K. T., Stahlfeld, C. N., Jiang, D., Singh, A., Kaufmann, K. R., Niles, D. J., Héninger, E., Rydzewski, N. R., Wang, L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1305 · Cited by 57
“Resistance toARSIs,thebackboneofsystemictherapyforthisdisease,iswidespread.”
InfluentialSelf-citationLi, Y., Wang, L., Liu, J., Zhang, P., An, M., Han, C., Li, Y., Guan, X., & Zhang, K. (2017) · Oncogene · doi:10.1038/onc.2017.223 · Cited by 54
Mol, E. D., Szulc, E., Sanza, C. D., Martínez-Cristóbal, P., Bertoncini, C. W., Fenwick, R. B., Frigolé‐Vivas, M., Masin, M., Hunter, I., Buzón, V., et al. (2017) · Structure · doi:10.1016/j.str.2017.11.007 · Cited by 55
Lee, A. R., Gan, Y., Tang, Y., & Dong, X. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.011 · Cited by 54
Wu, R., Young, I.-C., Chen, Y.-F., Chuang, S.-T., Toubaji, A., & Wu, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12184-8 · Cited by 53
Self-citationJMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Paschalis, A., Welti, J. C., Neeb, A., Yuan, W., Figueiredo, I., Pereira, R., Ferreira, A., Riisnaes, R., Rodrigues, D. N., Jiménez‐Vacas, J. M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1807 · Cited by 52
Self-citationChen, R., Li, Y., Buttyan, R., & Dong, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19386 · Cited by 53
Immunotherapy for Prostate Cancer: Where We Are Headed
Schepisi, G., Farolfi, A., Conteduca, V., Martignano, F., Lisi, D. D., Ravaglia, G., Rossi, L., Menna, C., Bellia, S. R., Barone, D., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122627 · Cited by 54
Clinical and genomic features of SPOP‐mutant prostate cancer
Nakazawa, M., Fang, M., Marshall, C. H., Lotan, T. L., Velho, P. I., & Antonarakis, E. S. (2021) · The Prostate · doi:10.1002/pros.24269 · Cited by 55
Luthold, C., Hallal, T., Labbé, D. P., & Bordeleau, F. (2022) · Cancers · doi:10.3390/cancers14122887 · Cited by 62
Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression
Zhu, W., Wan, F., Xu, W., Liu, Z., Wang, J., Zhang, H., Huang, S., & Ye, D. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1028 · Cited by 52
Han, D. G., Labaf, M., Zhao, Y., Owiredu, J. N., Zhang, S., Patel, K. J., Venkataramani, K., Steinfeld, J. S., Han, W., Li, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci168649 · Cited by 56
Self-citationNeuroendocrine Differentiation in Prostate Cancer Requires ASCL1
Rodarte, K. E., Heyman, S. N., Guo, L. M., Flores, L., Savage, T. K., Villarreal, J., Deng, S., Xu, L., Shah, R. B., Oliver, T. G., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1388 · Cited by 55
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion
Blee, A. M., Liu, S., Wang, L., & Huang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9513 · Cited by 54
Tan, H., Thomas‐Ahner, J. M., Moran, N. E., Cooperstone, J. L., Erdman, J. W., Young, G. S., & Clinton, S. K. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0402 · Cited by 53
Callari, M., Sammut, S., Mattos‐Arruda, L. D., Bruna, A., Rueda, O. M., Chin, S., & Caldas, C. (2017) · Genome Medicine · doi:10.1186/s13073-017-0425-1 · Cited by 53
Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease
Pérez-López, R., Rodrigues, D. N., Figueiredo, I., Mateo, J., Collins, D. J., Koh, D., Bono, J. S. D., & Tunariu, N. (2017) · Investigative Radiology · doi:10.1097/rli.0000000000000415 · Cited by 53
Self-citationPorter, L. H., Hashimoto, K., Lawrence, M. G., Pezaro, C. J., Clouston, D. R., Wang, H., Papargiris, M., Thorne, H., Li, J., kConFab, et al. (2017) · British Journal of Urology · doi:10.1111/bju.14043 · Cited by 53
Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
Chedgy, E. C. P., Vandekerkhove, G. R., Herberts, C., Annala, M., Donoghue, A., Sigouros, M., Ritch, E. J., Struss, W. J., Konomura, S., Liew, J., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5137 · Cited by 53
Self-citationMutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis
Weng, C., Ding, P.-Y., Liu, Y.-H., Hawse, J. R., Subramaniam, M., Wu, C.-C., Lin, Y.-C., Chen, C.-Y., Hung, W.-C., & Cheng, K. (2018) · Oncogene · doi:10.1038/s41388-018-0575-7 · Cited by 53
Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
Boerrigter, E., Groen, L., van Erp, N. P., Verhaegh, G. W. C. T., & Schalken, J. A. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1675515 · Cited by 56
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
Corella, A. N., Ordonio, M. V. A. C., Coleman, I. M., Lucas, J. M., Kaipainen, A., Nguyen, H. M., Sondheim, D., Brown, L. G., True, L. D., Lee, J. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0775 · Cited by 55
Self-citationMetastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
Klusa, D., Lohaus, F., Furesi, G., Rauner, M., Benešová, M., Krause, M., Kurth, I., & Peitzsch, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.627379 · Cited by 58
Yan, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., Ma, L., Chen, J., Yu, Z., He, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708478 · Cited by 53
Self-citationDevelopment of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research
Elbadawy, M., Abugomaa, A., Yamawaki, H., Usui, T., & Sasaki, K. (2020) · Cancers · doi:10.3390/cancers12040777 · Cited by 54
Fernandes, R. C., Toubia, J., Townley, S. L., Hanson, A. R., Dredge, B. K., Pillman, K. A., Bert, A. G., Winter, J. M., Iggo, R. D., Das, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108585 · Cited by 52
Maeda, S., Motegi, T., Iio, A., Kaji, K., Goto‐Koshino, Y., Eto, S., Ikeda, N., Nakagawa, T., Nishimura, R., Yonezawa, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003731 · Cited by 55
Fizazi, K. S., Chi, K. N., Shore, N. D., Herrmann, K., Bono, J. S. D., Castellano, D., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.07.003 · Cited by 59
“Another potential confounding factor, and a limitation of the study, is that patients with known genomic alterations (e.g. in the DNA damage response [DDR] pathway 36,37 ) that confer eligibility for alternative standard therapies were excluded.”
InfluentialSelf-citationMiR137is an androgen regulated repressor of an extended network of transcriptional coregulators
Nilsson, E. M., Laursen, K. B., Whitchurch, J. B., McWilliam, A., Ødum, N., Persson, J. L., Heery, D. M., Gudas, L. J., & Mongan, N. P. (2015) · Oncotarget · doi:10.18632/oncotarget.5958 · Cited by 52
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
Graham, L. S., & Schweizer, M. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0759-3 · Cited by 54
Stoyanova, T. I., Riedinger, M., Lin, S., Faltermeier, C. M., Smith, B. A., Zhang, K. X., Going, C. C., Goldstein, A. S., Lee, J. K., Drake, J. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614529113 · Cited by 54
Self-citationA Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland
Pakula, H., Xiang, D., & Li, Z. (2017) · Cancers · doi:10.3390/cancers9020014 · Cited by 55
Hovelson, D. H., Liu, C., Wang, Y., Kang, Q., Henderson, J., Gursky, A. M., Brockman, S., Ramnath, N., Krauss, J. C., Talpaz, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21163 · Cited by 52
Self-citationMechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase
Song, J. H., Singh, N., Luevano, L. A., Padi, S. K. R., Okumura, K., Olive, V., Black, S. M., Warfel, N. A., Goodrich, D. W., & Kraft, A. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0374 · Cited by 52
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
McEvoy, C. R. E., Xu, H., Smith, K. M., Etemadmoghadam, D., Leong, H. S., Choong, D., Byrne, D. J., Iravani, A., Beck, S., Mileshkin, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123089 · Cited by 51
Clinical Implications of Mismatch Repair Deficiency in Prostate Cancer
Sedhom, R., & Antonarakis, E. S. (2019) · Future Oncology · doi:10.2217/fon-2019-0068 · Cited by 56
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
Patel, V., Busch, E. L., Friebel, T. M., Cronin, A. M., Leslie, G., McGuffog, L., Adlard, J., Agata, S., Agnarsson, B. A., Ahmed, M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1840 · Cited by 52
Chun, J. N., Cho, M., Park, S., So, I., & Jeon, J. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188336 · Cited by 51
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Claps, M., Mennitto, A., Guadalupi, V., Sepe, P., Stellato, M., Zattarin, E., Gillessen, S., Sternberg, C. N., Berruti, A., de Braud, F., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102057 · Cited by 53
Zhou, L., Zhang, C., Yang, X. W., Liu, L., Hu, J., Hou, Y., Tao, H., Sugimura, H., Chen, Z., Wang, L., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.449 · Cited by 52
Recent advances in microfluidic methods in cancer liquid biopsy
Iliescu, F. S., Poenar, D. P., Yu, F., Ni, M., Chan, K. H., Cima, I., Taylor, H. K., Cima, I., & Iliescu, C. (2019) · Biomicrofluidics · doi:10.1063/1.5087690 · Cited by 51
Identification of Somatic Mutations in CLCN2 in Aldosterone-Producing Adenomas
Rege, J., Nanba, K., Blinder, A., Plaska, S. W., Udager, A. M., Vats, P., Kumar‐Sinha, C., Giordano, T. J., Rainey, W. E., & Else, T. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa123 · Cited by 53
Self-citationGenomic Profiling of Prostate Cancer: An Updated Review
Hatano, K., & Nonomura, N. (2021) · The World Journal of Men s Health · doi:10.5534/wjmh.210072 · Cited by 56
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 56
Self-citationIRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing
Pan, Y., Phillips, J. W., Zhang, B. D., Noguchi, M., Kutschera, E., McLaughlin, J., Nesterenko, P. A., Mao, Z., Bangayan, N. J., Wang, R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221116120 · Cited by 50
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Lee, E., Ha, S., & Logan, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141589 · Cited by 52
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
